Market Summary
USD12.14+0.01
Market Closed0.08%
CPRX Stock Price
CPRX RSI Chart
CPRX Valuation
CPRX Price/Sales (Trailing)
CPRX Profitability
CPRX Fundamentals
CPRX Revenue
CPRX Earnings
Price Action
52 Week Range
11.0922.11
(Low)(High)
Last 7 days
-3.9%
Last 30 days
-14.8%
Last 90 days
-7.6%
Trailing 12 Months
2.2%
CPRX Financial Health
CPRX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CPRX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-03 | DENKHAUS DONALD A | acquired | 67,800 | 1.13 | 60,000 | - |
2023-06-27 | Del Carmen Jeffrey | acquired | - | - | 10,000 | chief commercial officer |
2023-06-27 | Del Carmen Jeffrey | sold (taxes) | - | - | -3,942 | chief commercial officer |
2023-05-16 | MCENANY PATRICK J | acquired | 137,341 | 0.79 | 173,849 | president and ceo |
2023-05-15 | MCENANY PATRICK J | sold | -345,978 | 13.23 | -26,151 | president and ceo |
2023-05-15 | MCENANY PATRICK J | acquired | 20,659 | 0.79 | 26,151 | president and ceo |
2023-05-12 | Daly Richard J | acquired | 39,500 | 0.79 | 50,000 | - |
2023-05-11 | Tierney David S | acquired | 15,800 | 0.79 | 20,000 | - |
2023-05-11 | Miller Steve | acquired | 79,000 | 0.79 | 100,000 | chief operating officer |
2023-05-04 | COELHO PHILIP H | acquired | 39,500 | 0.79 | 50,000 | - |
Which funds bought or sold CPRX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 241 | 5,693,000 | 8,907,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | -1,783 | 7,634 | -% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | reduced | -55.56 | -4,773 | 2,688 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -312,056 | 1,335,680 | 0.01% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 50.9 | 165,044 | 904,512 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.08 | -420,392 | 1,618,140 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 5.57 | -71,000 | 423,000 | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 42,685 | 42,685 | 0.02% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -23.23 | -292,951 | 482,550 | -% |
2023-08-17 | Orion Portfolio Solutions, LLC | added | 29.6 | 8,934 | 185,660 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Catalyst Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | armistice capital, llc | 0% | 0 | SC 13G/A | |
| Feb 10, 2023 | flynn james e | 5.65% | 5,884,448 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.50% | 6,768,741 | SC 13G | |
| Feb 08, 2023 | state street corp | 7.57% | 7,873,314 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 15.1% | 15,690,326 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 15.1% | 15,690,326 | SC 13G/A | |
| Nov 14, 2022 | flynn james e | 5.82% | 6,060,491 | SC 13G | |
| Feb 15, 2022 | armistice capital, llc | 9.3% | 9,572,000 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 4.69% | 4,836,313 | SC 13G/A | |
| Feb 09, 2022 | state street corp | 4.90% | 5,050,989 | SC 13G/A |
Recent SEC filings of Catalyst Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 08, 2023 | S-3ASR | S-3ASR | |
| Aug 25, 2023 | 8-K | Current Report | |
| Aug 09, 2023 | 8-K | Current Report | |
| Aug 09, 2023 | 10-Q | Quarterly Report | |
| Aug 04, 2023 | 4 | Insider Trading | |
| Jul 28, 2023 | 8-K | Current Report | |
| Jul 21, 2023 | 8-K | Current Report | |
| Jul 17, 2023 | ARS | ARS | |
| Jul 12, 2023 | DEF 14A | DEF 14A | |
| Jun 29, 2023 | 4 | Insider Trading |
Peers (Alternatives to Catalyst Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 272.0B | 56.0B | 5.43% | 9.20% | 31.31 | 4.85 | -2.31% | -31.27% |
BGNE | 255.4B | 1.8B | -4.05% | 37.32% | -147.41 | 141.03 | 69.45% | 14.65% |
VRTX | 90.7B | 9.5B | 0.17% | 23.71% | 26.94 | 9.54 | 13.83% | 5.33% |
REGN | 89.1B | 12.7B | 0.52% | 19.69% | 20.72 | 7.03 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -9.77% | -14.95% | -20.56 | 17.67 | 39.94% | -8.44% |
SRPT | 11.1B | 1.0B | -3.58% | 6.05% | -12.27 | 11.1 | 20.15% | -79.16% |
UTHR | 10.8B | 2.1B | -2.16% | 7.92% | 12.38 | 5.11 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | -2.45% | -24.77% | -5.46 | 13.42 | -2.11% | 21.02% |
MDGL | 2.8B | - | -15.83% | 131.72% | -8.45 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -3.27% | -11.64% | -3.64 | 6.51 | 20.50% | -42.46% |
MRTX | 2.4B | 27.2M | 11.70% | -39.35% | -3.27 | 88.62 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -14.00% | -40.97% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -14.82% | 2.19% | 11.19 | 4.27 | 77.72% | 112.02% |
MGNX | 284.9M | 152.5M | -8.91% | 51.32% | 38.25 | 1.87 | 127.84% | 103.41% |
CRBP | 28.4M | - | -10.88% | 3445.93% | -0.62 | - | - | -31.51% |
Catalyst Pharmaceuticals News
Returns for CPRX
Cumulative Returns on CPRX
14.2%
10-Year Cumulative Returns
39.7%
7-Year Cumulative Returns
26.7%
5-Year Cumulative Returns
56.6%
3-Year Cumulative Returns
Risks for CPRX
What is the probability of a big loss on CPRX?
90.8%
Probability that Catalyst Pharmaceuticals stock will be more than 20% underwater in next one year
67.7%
Probability that Catalyst Pharmaceuticals stock will be more than 30% underwater in next one year.
63.1%
Probability that Catalyst Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CPRX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Catalyst Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Catalyst Pharmaceuticals
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2010Q4 |
| Revenue | 18.1% | 303 | 256 | 214 | 192 | 170 | 154 | 141 | 134 | 127 | 120 | 119 | 118 | 120 | 119 | 102 | 73.00 | 56.00 | 26.00 | 2.00 | 0.00 |
| Operating Expenses | 20.8% | 165 | 136 | 112 | 108 | 98.00 | 94.00 | 88.00 | 84.00 | 82.00 | 82.00 | 78.00 | - | - | - | - | - | 55.00 | 43.00 | 36.00 | - |
| S&GA Expenses | 21.7% | 87.00 | 71.00 | 58.00 | 57.00 | 55.00 | 53.00 | 50.00 | 50.00 | 48.00 | 47.00 | 44.00 | 42.00 | 40.00 | 39.00 | 37.00 | 32.00 | 28.00 | 22.00 | 16.00 | - |
| R&D Expenses | -0.1% | 20.00 | 20.00 | 20.00 | 21.00 | 17.00 | 17.00 | 17.00 | 16.00 | 15.00 | 15.00 | 16.00 | 19.00 | 19.00 | 20.00 | 19.00 | 21.00 | 21.00 | 20.00 | 20.00 | - |
| EBITDA | -100.0% | - | 125 | 105 | 85.00 | 73.00 | 60.00 | 53.00 | 49.00 | 46.00 | 41.00 | 42.00 | 42.00 | 44.00 | 45.00 | 33.00 | 11.00 | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.49* | 0.49* | 0.44* | 0.43* | 0.39* | 0.38* | 0.37* | 0.37* | 0.34* | 0.35* | 0.35* | 0.37* | 0.38* | 0.33* | 0.14* | - | - | - | - |
| Earnings Before Taxes | 16.3% | 145 | 125 | 105 | 85.00 | 73.00 | 60.00 | 53.00 | 49.00 | 46.00 | 41.00 | 42.00 | 42.00 | 44.00 | 45.00 | 33.00 | 11.00 | -11.57 | -28.95 | -34.00 | - |
| EBT Margin | -100.0% | - | 0.49* | 0.49* | 0.44* | 0.43* | 0.39* | 0.37* | 0.36* | 0.36* | 0.34* | 0.35* | 0.35* | 0.37* | 0.38* | 0.33* | 0.14* | - | - | - | - |
| Net Income | 16.2% | 116 | 99.00 | 83.00 | 67.00 | 54.00 | 45.00 | 39.00 | 42.00 | 75.00 | 72.00 | 75.00 | 71.00 | 42.00 | 43.00 | 32.00 | 9.00 | -12.02 | -28.95 | -34.00 | - |
| Net Income Margin | -100.0% | - | 0.39* | 0.39* | 0.35* | 0.32* | 0.29* | 0.28* | 0.31* | 0.59* | 0.60* | 0.63* | 0.60* | 0.35* | 0.36* | 0.31* | 0.13* | - | - | - | - |
| Free Cashflow | -100.0% | - | 120 | 116 | 95.00 | 75.00 | 64.00 | 59.00 | 53.00 | 43.00 | 40.00 | 45.00 | 44.00 | 49.00 | 50.00 | 35.00 | 14.00 | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 9.0% | 444 | 407 | 376 | 333 | 267 | 247 | 238 | 223 | 209 | 197 | 192 | 175 | 131 | 118 | 112 | 97.00 | 78.00 | 61.00 | 60.00 | 68.00 | 74.00 |
| Current Assets | 21.1% | 241 | 199 | 321 | 276 | 243 | 221 | 210 | 193 | 176 | 162 | 159 | 143 | 131 | 117 | 111 | 91.00 | 72.00 | 55.00 | 55.00 | 62.00 | 69.00 |
| Cash Equivalents | 20.6% | 179 | 148 | 298 | 256 | 211 | 178 | 171 | 155 | 135 | 127 | 130 | 117 | 115 | 102 | 90.00 | 45.00 | 23.00 | 19.00 | 17.00 | 11.00 | 10.00 |
| Inventory | 4.1% | 11.00 | 10.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 4.00 | 5.00 | 5.00 | 2.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | - | - |
| Net PPE | -6.4% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Liabilities | -6.7% | 69.00 | 74.00 | 75.00 | 63.00 | 26.00 | 27.00 | 31.00 | 25.00 | 20.00 | 19.00 | 23.00 | 18.00 | 20.00 | 18.00 | 25.00 | 19.00 | 15.00 | 10.00 | 10.00 | 4.00 | 3.00 |
| Current Liabilities | -7.4% | 53.00 | 57.00 | 58.00 | 45.00 | 22.00 | 23.00 | 27.00 | 21.00 | 16.00 | 14.00 | 23.00 | 18.00 | 20.00 | 18.00 | 24.00 | 18.00 | 14.00 | 9.00 | 10.00 | 3.00 | 3.00 |
| Shareholder's Equity | 12.5% | 375 | 334 | 300 | 270 | 241 | 220 | 207 | 199 | 189 | 179 | 170 | 157 | 111 | 100 | 88.00 | 78.00 | 63.00 | 51.00 | 51.00 | 64.00 | 71.00 |
| Retained Earnings | 47.5% | 117 | 79.00 | 50.00 | 24.00 | 2.00 | -15.62 | -26.31 | -32.54 | -37.82 | -46.33 | -53.70 | -65.14 | -108 | -118 | -128 | -136 | -150 | -161 | -160 | -146 | -138 |
| Additional Paid-In Capital | 1.5% | 258 | 254 | 250 | 246 | 239 | 236 | 233 | 231 | 227 | 225 | 223 | 222 | 220 | 218 | 216 | 214 | 213 | 212 | 211 | 210 | 209 |
| Shares Outstanding | 0.5% | 107 | 106 | 105 | 104 | 103 | 103 | 103 | 103 | 103 | 104 | 104 | 104 | 103 | 103 | 103 | 103 | 103 | 103 | 103 | 103 | 103 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 3.8% | 124 | 120 | 116 | 95.00 | 76.00 | 65.00 | 60.00 | 54.00 | 44.00 | 42.00 | 45.00 | 44.00 | 49.00 | 50.00 | 35.00 | 14.00 | -9.25 | -28.08 | -26.15 | -21.83 | -17.51 |
| Share Based Compensation | 14.3% | 10.00 | 9.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 |
| Cashflow From Investing | 25.0% | -162 | -216 | 9.00 | -0.35 | -0.22 | - | -11.02 | -10.98 | -20.92 | -16.92 | -5.01 | 27.00 | 42.00 | 32.00 | 37.00 | 20.00 | 22.00 | 27.00 | -15.08 | -29.17 | -36.77 |
| Cashflow From Financing | 81.9% | 6.00 | 3.00 | 2.00 | -3.08 | -9.17 | -9.88 | -8.14 | -5.59 | -2.88 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 54.00 | 56.00 |
| Buy Backs | -100.0% | - | 4.00 | 7.00 | 10.00 | 15.00 | 14.00 | 12.00 | 12.00 | 8.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - |
CPRX Income Statement
2023-06-30CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |||
| Revenues: | ||||||
| Total revenues | $ 99,582 | $ 53,113 | $ 184,948 | $ 96,202 | ||
| Operating costs and expenses: | ||||||
| Cost of sales | [1] | 12,045 | 7,643 | 21,991 | 13,533 | |
| Research and development | 3,954 | 3,983 | 7,516 | 7,386 | ||
| Selling, general and administrative | [1] | 28,396 | 12,918 | 58,114 | 29,348 | |
| Amortization of intangible assets | 8,488 | 0 | 15,019 | 0 | ||
| Total operating costs and expenses | 52,883 | 24,544 | 102,640 | 50,267 | ||
| Operating income | 46,699 | 28,569 | 82,308 | 45,935 | ||
| Other income (expense), net | 1,813 | (324) | 3,517 | (231) | ||
| Net income before income taxes | 48,512 | 28,245 | 85,825 | 45,704 | ||
| Income tax provision | 10,750 | 6,626 | 18,495 | 10,844 | ||
| Net income | $ 37,762 | $ 21,619 | $ 67,330 | $ 34,860 | ||
| Net income per share: | ||||||
| Basic | $ 0.36 | $ 0.21 | $ 0.64 | $ 0.34 | ||
| Diluted | $ 0.33 | $ 0.2 | $ 0.59 | $ 0.32 | ||
| Weighted average shares outstanding: | ||||||
| Basic | 106,258,790 | 102,795,600 | 105,911,936 | 102,788,719 | ||
| Diluted | 113,673,534 | 109,264,730 | 113,840,155 | 109,149,185 | ||
| Net income | $ 37,762 | $ 21,619 | $ 67,330 | $ 34,860 | ||
| Other comprehensive income (Note 4): | ||||||
| Unrealized gain (loss) on available-for-sale securities, net of tax of ($3), ($101), $2 and $2, respectively | 8 | 323 | (5) | 18 | ||
| Comprehensive income | 37,770 | 21,942 | 67,325 | 34,878 | ||
| Product revenue, net [Member] | ||||||
| Revenues: | ||||||
| Total revenues | 99,477 | 53,049 | 184,781 | 96,082 | ||
| License and other revenue [Member] | ||||||
| Revenues: | ||||||
| Total revenues | $ 105 | $ 64 | $ 167 | $ 120 | ||
| ||||||
CPRX Balance Sheet
2023-06-30CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 178,787 | $ 298,395 |
| Accounts receivable, net | 42,796 | 10,439 |
| Inventory | 10,751 | 6,805 |
| Prepaid expenses and other current assets | 8,634 | 5,167 |
| Total current assets | 240,968 | 320,806 |
| Operating lease right-of-use asset | 2,641 | 2,770 |
| Property and equipment, net | 1,203 | 847 |
| License and acquired intangibles, net | 175,595 | 32,471 |
| Deferred tax assets, net | 23,489 | 18,736 |
| Total assets | 443,896 | 375,630 |
| Current Liabilities: | ||
| Accounts payable | 4,421 | 3,975 |
| Accrued expenses and other liabilities | 48,082 | 53,613 |
| Total current liabilities | 52,503 | 57,588 |
| Operating lease liability, net of current portion | 3,376 | 3,557 |
| Other non-current liabilities | 12,723 | 14,064 |
| Total liabilities | 68,602 | 75,209 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at June 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, $0.001 par value, 200,000,000 shares authorized; 106,501,259 shares and 105,263,031 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 107 | 105 |
| Additional paid-in capital | 257,976 | 250,430 |
| Retained earnings | 117,192 | 49,862 |
| Accumulated other comprehensive income (loss) (Note 4) | 19 | 24 |
| Total stockholders' equity | 375,294 | 300,421 |
| Total liabilities and stockholders' equity | $ 443,896 | $ 375,630 |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.